GLS-5700 in Dengue Virus-Naïve Adults

Phase 1 Completed 40 enrolled GeneOne Life Science, Inc. Inovio Pharmaceuticals · collab

Non-randomizedParallel-groupOpen-labelPrevention

Summary

The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus. ZIKA-001 is the first in man clinical trial of this vaccine which encodes for the premembrane-membrane and envelope regions of Zika virus.

Timeline

Start: 2016-07
Primary completion: 2017-11
Completion: 2017-12

Publications

Tebas P, Roberts CC, Muthumani K, Reuschel EL, Kudchodkar SB, Zaidi FI, White S, Khan AS, Racine T, Choi H, Boyer J, Park YK, Trottier S, Remigio C, Krieger D, Spruill SE, Bagarazzi M, Kobinger GP, Weiner DB, Maslow JN. Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine. N Engl J Med. 2021 Sep 16;385(12):e35. doi: 10.1056/NEJMoa1708120.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GLS-5700	Vaccine	1 mg	Intravenous
Subject	GLS-5700	Vaccine	2 mg	Intravenous

Indications

No indication recorded.